Welcome to our dedicated page for Genetron Holdings news (Ticker: GTH), a resource for investors and traders seeking the latest updates and insights on Genetron Holdings stock.
Genetron Holdings Limited (NASDAQ: GTH) is a leading precision oncology platform company based in China. With a focus on cancer molecular profiling, Genetron leverages advanced technologies in molecular biology and data science to revolutionize cancer treatment.
The company's extensive portfolio spans various stages of cancer management, including early screening, diagnosis, treatment recommendations, and continuous monitoring. Some of its flagship services and products include:
- HCCscreen: A proprietary assay for the early detection of liver cancer.
- 8-gene Lung Cancer Assay: An in-vitro diagnostic tool based on semiconductor sequencing for lung cancer detection.
- Genetron 3D Biochip Reading Instrument and Genetron S5 and S2000: Advanced sequencers for gene detection and panel sequencing.
- IDH1/TERT Gene Assays: Diagnostic assays for glioma.
In addition, Genetron has developed a ctDNA Lung Cancer Assay targeting mutations in the epidermal growth factor receptor gene. The company collaborates with global biopharmaceutical firms to offer tailored genomics research and clinical development services.
Recently, Genetron announced a definitive Agreement and Plan of Merger with New Genetron Holding Limited and Genetron New Co Limited. As part of the merger, Genetron will become a wholly-owned subsidiary of the parent company in a transaction valued at approximately US$126.0 million. This merger signifies a pivotal transformation, taking the company private and enhancing its strategic flexibility.
The merger completion, expected in the first quarter of 2024, is subject to customary closing conditions, including shareholder votes and regulatory approvals. Upon completion, Genetron's American Depositary Shares (ADSs) will be delisted from the Nasdaq Global Market, and the company will terminate its ADS program. The company aims to finalise this transition efficiently to focus on its long-term vision and goals.
For the latest updates and detailed information on Genetron Holdings Limited and its innovative contributions to precision oncology, please visit their Investor Relations page.
Genetron Holdings Limited (GTH) announced a partnership with IMPACT Therapeutics to collaborate on synthetic lethal inhibitors and companion diagnostics development.
Genetron Health aims to enhance patient access to precision oncology therapies, leveraging its certified labs in China and the U.S. The partnership seeks to advance targeted anti-cancer therapeutics, building on IMPACT’s extensive pipeline.
Synthetic lethality represents a promising approach for cancer treatment, with the global PARP inhibitor market projected to exceed $4.5 billion by 2023.
Genetron Holdings Limited (NASDAQ: GTH) recently announced a collaboration with 14 top hospitals in China to present 13 key research findings at ESMO 2021. This research, utilizing Genetron's innovative technologies, focuses on genomics in the Chinese population and aims to enhance clinical management of hereditary colorectal cancer and other cancers. Notable findings include the efficacy of a full-cycle gene test for thyroid cancer predicting biopsy results, and mapping gene mutations for improved targeted therapies. These advancements could lead to better early cancer diagnosis and treatment options for patients.
Genetron Holdings Limited (NASDAQ: GTH) announced its inclusion in the FTSE Global Equity Index Series effective September 17, 2021. This includes the FTSE Global Small Cap Index, FTSE Global All-Cap Index, and FTSE Global Total-Cap Index. CEO Sizhen Wang highlighted this as a significant milestone following their Nasdaq IPO in June 2020, emphasizing the company's commitment to enhancing healthcare options globally. Genetron specializes in precision oncology, providing a range of services in cancer management.
Genetron Holdings Limited (NASDAQ:GTH) announced that Co-Founder and Chief Scientific Officer, Dr. Hai Yan, received the prestigious International Prize for Translational Neuroscience 2021. The award recognizes his significant contributions to neurobiology, particularly research on malignant gliomas, which are the most common primary brain tumors. Dr. Yan's team discovered mutations in metabolic enzymes IDH1 and IDH2 present in 70% of gliomas, aiding in prognosis and treatment. The award ceremony took place on August 26, 2021, in Cologne, Germany, showcasing Genetron's commitment to impactful cancer research.
Genetron Holdings Limited (NASDAQ:GTH) announced its unaudited preliminary financial results for Q2 2021. The company reported a total revenue of RMB 140.5 million (US$21.8 million), a 38.1% increase compared to Q2 2020. Notably, IVD revenue surged 141.5% to RMB 43.8 million (US$6.8 million), driven by the sales of its S5 instrument and 8-gene Lung Cancer Assay. Despite achieving a gross margin of 67.2%, operating expenses rose 65.8%, leading to an operating loss of RMB 100.2 million (US$15.5 million). Genetron maintains its 2021 revenue guidance of RMB 615 million to RMB 625 million, pending potential COVID-related impacts.
Genetron Holdings Limited (Nasdaq: GTH) announced management will host calls with brokers following second quarter earnings and participate in the 2021 Wells Fargo Virtual Healthcare Conference. Key call times include meetings with UBS, Haitong Securities, and others on August 25. The conference will take place on September 9-10, 2021, featuring CEO Sichen Wang and CFO Evan Xu. Genetron Health specializes in precision oncology, offering molecular profiling tests, early cancer screening, and companion diagnostics.
Genetron Holdings Limited (NASDAQ: GTH) announced a strategic partnership with Shanghai Yikon Genomics Technology. This collaboration will allow Yikon Genomics exclusive rights to utilize Genetron Health's S5 instrument for reproductive health applications in China. The partnership aims to enhance revenue for Genetron Health in 2021 and expand the S5's usage beyond oncology to include reproductive health diagnostics. The S5 platform, which has received NMPA approval, showcases flexibility in applications and aims to improve access to innovative genetic technology.
Genetron Holdings Limited (NASDAQ: GTH) will report its unaudited financial results for Q2 2021 on August 24, 2021, prior to U.S. market opening. The company specializes in precision oncology, focusing on molecular profiling tests and early cancer screening. A conference call for investors is scheduled for 8:30 a.m. ET on the same day, with details available for international participants. Genetron aims to transform cancer treatment through advanced technology and partnerships with biopharmaceutical firms.
Genetron Health (NASDAQ: GTH), a leading precision oncology platform in China, announced that its Beijing clinical laboratory achieved full marks in the National Center for Clinical Laboratories' first nationwide external quality assessment for NGS-based genomic profiling. Ranking first among 63 participating labs, Genetron demonstrated zero reproducibility errors and false negatives, confirming its high-quality operational standards. The company has maintained full marks for six consecutive years and holds significant international certifications, including CAP, CLIA, and ISO15189, enhancing its reputation in precision medicine.
Genetron Holdings Limited (NASDAQ: GTH) announced its collaboration with Dafang County authorities in Guizhou Province for the "Early Screening for Regional Liver Cancer Prevention and Containment Demonstration Project." Supported by the Central Committee of the Chinese Peasants and Workers Democratic Party and China’s National Cancer Center, this initiative aims to enhance cancer early screening technologies in rural China. The project will utilize Genetron's HCCscreen™, achieving 88% sensitivity and 93% specificity in detecting liver cancer, promoting cancer prevention and equitable healthcare access.
FAQ
What is the market cap of Genetron Holdings (GTH)?
What does Genetron Holdings Limited specialize in?
What are some of Genetron's key products?
What recent corporate action has Genetron announced?
What is HCCscreen?
What is the significance of Genetron's merger?
What happens to Genetron's ADSs after the merger?
Who are the major stakeholders involved in the merger?
When is the merger expected to complete?
What services does Genetron offer in genomics research?
Where can I find more information about Genetron's financial filings?
